Mesoblast Projects Sustained Ryoncil Sales Momentum Through Q4 2025

Mesoblast Limited (MESO), a biotechnology innovator specializing in allogeneic cellular medicines for inflammatory conditions, anticipates sustained expansion in Ryoncil revenue during the fourth quarter of 2025. The company forecasts gross revenue exceeding US$30.0 million from Ryoncil in Q4, reflecting a robust 37% quarter-over-quarter uptick from the US$21.9 million recorded in Q3 2025.

Market Expansion and Clinical Trajectory

Ryoncil, approved by the FDA in December 2024, represents the first mesenchymal stromal cell (MSC) therapy authorized for pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD). To capitalize on this market opportunity, Mesoblast has secured commercial partnerships across Japan, Europe, and China, positioning the therapy for broader geographic penetration.

Beyond its approved indication, Ryoncil continues advancing through the clinical pipeline. The company is conducting phase 3 evaluations in adult patients with SR-aGVHD and in inflammatory bowel disease (IBD), specifically targeting Crohn’s disease applications. These ongoing trials underscore management’s commitment to expanding the therapeutic utility of its lead asset.

Pipeline Developments and Stock Performance

Mesoblast’s investigational portfolio extends beyond Ryoncil, with two notable phase 3 candidates in development: REVASCOR, designed for advanced chronic heart failure, and MPC-06-ID, targeting chronic low back pain associated with degenerative disc disease. These programs could represent significant future revenue drivers if clinical endpoints are met.

Regarding stock performance, MESO has fluctuated between $9.61 and $22.0 over the trailing twelve months. The stock concluded the previous session at $15.62, up 1.63%, though it retreated to $15.41 in extended trading, reflecting a 1.34% decline in after-hours activity.